ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA(R) in BCG-Unresponsive Papillary Bladder Cancer

Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA ...
Blockonomi

ImmunityBio (IBRX) Stock Jumps 20% as FDA Clears Path for Bladder Cancer Treatment

ImmunityBio stock rose 19.8% after FDA meeting on ANKTIVA bladder cancer treatment. Company to submit additional data within ...
EatingWell on MSN

This common nighttime habit can be a sign of disease—here’s when to worry

We all do it sometimes. But how much is too much?

Ketamine is giving more young people bladder problems—an expert explains

Urology departments in England and Wales have reported seeing an increase in the number of 16- to 24-year-olds being admitted ...